Literature DB >> 22277300

Place your BETs: the therapeutic potential of bromodomains.

R K Prinjha1, J Witherington, K Lee.   

Abstract

Therapeutic targeting of the processes that regulate histone modification is a growing area of scientific exploration. Although most interest has concentrated on the various families of enzymes that contribute to these processes, this review focuses on emerging data demonstrating the chemical tractability and therapeutic potential of a hitherto underexplored family of proteins, namely the bromodomain (BRD) family of reader proteins. These proteins perform a crucial role in translating histone modifications with powerful transcriptional consequences. We review current knowledge of the biology of this emergent target class and highlight recent breakthroughs that now make the BRD family of reader proteins attractive for drug discovery. Copyright Â
© 2012. Published by Elsevier Ltd.

Mesh:

Substances:

Year:  2012        PMID: 22277300     DOI: 10.1016/j.tips.2011.12.002

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  77 in total

1.  Brd4 bridges the transcriptional regulators, Aire and P-TEFb, to promote elongation of peripheral-tissue antigen transcripts in thymic stromal cells.

Authors:  Hideyuki Yoshida; Kushagra Bansal; Uwe Schaefer; Trevor Chapman; Inmaculada Rioja; Irina Proekt; Mark S Anderson; Rab K Prinjha; Alexander Tarakhovsky; Christophe Benoist; Diane Mathis
Journal:  Proc Natl Acad Sci U S A       Date:  2015-07-27       Impact factor: 11.205

Review 2.  The bromodomain: from epigenome reader to druggable target.

Authors:  Roberto Sanchez; Jamel Meslamani; Ming-Ming Zhou
Journal:  Biochim Biophys Acta       Date:  2014-03-28

3.  Bromodomain and hedgehog pathway targets in small cell lung cancer.

Authors:  Gurmeet Kaur; Russell A Reinhart; Anne Monks; David Evans; Joel Morris; Eric Polley; Beverly A Teicher
Journal:  Cancer Lett       Date:  2015-12-10       Impact factor: 8.679

4.  I-BET151 selectively regulates IL-6 production.

Authors:  Elyse Barrett; Shaun Brothers; Claes Wahlestedt; Eléonore Beurel
Journal:  Biochim Biophys Acta       Date:  2014-05-22

5.  BET bromodomain inhibitors show anti-papillomavirus activity in vitro and block CRPV wart growth in vivo.

Authors:  Mary A Morse; Karla K Balogh; Sarah A Brendle; Colin A Campbell; Mao X Chen; Rebecca C Furze; Isobel L Harada; Ian D Holyer; Umesh Kumar; Kevin Lee; Rab K Prinjha; Martin Rüdiger; Jonathan T Seal; Simon Taylor; Jason Witherington; Neil D Christensen
Journal:  Antiviral Res       Date:  2018-04-11       Impact factor: 5.970

Review 6.  The ascent of acetylation in the epigenetics of rheumatoid arthritis.

Authors:  Aleksander M Grabiec; Kris A Reedquist
Journal:  Nat Rev Rheumatol       Date:  2013-02-26       Impact factor: 20.543

Review 7.  Targeting bromodomains: epigenetic readers of lysine acetylation.

Authors:  Panagis Filippakopoulos; Stefan Knapp
Journal:  Nat Rev Drug Discov       Date:  2014-04-22       Impact factor: 84.694

8.  Functions of BET proteins in erythroid gene expression.

Authors:  Aaron J Stonestrom; Sarah C Hsu; Kristen S Jahn; Peng Huang; Cheryl A Keller; Belinda M Giardine; Stephan Kadauke; Amy E Campbell; Perry Evans; Ross C Hardison; Gerd A Blobel
Journal:  Blood       Date:  2015-02-18       Impact factor: 22.113

Review 9.  Epigenetic drug discovery: breaking through the immune barrier.

Authors:  David F Tough; Paul P Tak; Alexander Tarakhovsky; Rab K Prinjha
Journal:  Nat Rev Drug Discov       Date:  2016-10-21       Impact factor: 84.694

10.  Protein-Observed Fluorine NMR Is a Complementary Ligand Discovery Method to 1H CPMG Ligand-Observed NMR.

Authors:  Andrew K Urick; Luis Pablo Calle; Juan F Espinosa; Haitao Hu; William C K Pomerantz
Journal:  ACS Chem Biol       Date:  2016-10-05       Impact factor: 5.100

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.